The results from Eli Lilly's Phase 3 trial of Donanemab showed that the drug significantly slowed cogntive and functional decline for early symptomatic Alzheimer's disease patients, decreasing their risk of disease progression. Their recent press release stated that "nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year".

This study demonstrates the importance of an early diagnosis and brings hope to people with Alzheimer's disease.

Read the full press release.